Trials / Completed
CompletedNCT02230228
Phase 1 Safety Study of ALK-001 in Healthy Volunteers
A Phase 1, Open Label, Repeat Dose Study to Investigate the Safety and Pharmacokinetics of 4-week Daily Dosing of ALK-001 in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Alkeus Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 21 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
This protocol is a phase 1 clinical study to assess the safety and pharmacokinetics of ALK-001 in healthy volunteers. Please contact trials@alkeus.com for any questions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALK-001 (No generic name) | Daily, oral administration of ALK-001 capsules. |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2014-09-01
- Completion
- 2015-02-01
- First posted
- 2014-09-03
- Last updated
- 2025-04-27
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02230228. Inclusion in this directory is not an endorsement.